AC Immune (NASDAQ:ACIU) unveiled clinical data on Friday suggesting its experimental vaccine could potentially slow the progression of Parkinson’s disease, a milestone that accompanied a significant corporate restructuring aimed at preserving its capital.
The Lausanne, Switzerland-based biopharmaceutical company reported interim Phase 2 "VacSYn" data for ACI-7104, its active immunotherapy targeting alpha-synuclein.
The study achieved a 100% immunogenic responder rate, meaning every participant produced the intended immune response.
More critically, early analysis suggests the vaccine may impact the clinical progression of the disease, a "disease-modifying" potential that has long been the holy grail of neurodegenerative research.
To support the advancement of this and other high-priority programs, AC Immune has undertaken a strategic "right-sizing," reducing its workforce by approximately 30%.
This move is designed to streamline operations as the company pivots toward late-stage clinical execution.
Financially, the company ended fiscal year 2025 with a cash balance of CHF 91.4 million.